Kilter Group’s ADMA Biologics ADMA Stock Holding History

Kilter Group’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-39	Closed	-$572	–	1397
2025 Q3	$572	Hold	39	–	–	﹤0.01%	1024
2025 Q2	$711	Buy	+39	New	+$795	﹤0.01%	909

Other funds holding ADMA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

SHCM

Sachem Head Capital Management New York $4.15B AUM 48.05% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Kilter Group's ADMA Position: Q4 2025 in Review

Kilter Group sold out of ADMA Biologics (ADMA) in Q4 2025, closing a stake of 39 shares — an estimated $572 sold.

Kilter Group first reported a position in ADMA in Q2 2025 and held it in 2 quarters. The position peaked at $711 in Q2 2025. 356 funds tracked by Wall St. Rank hold ADMA as of Q4 2025.

Kilter Group reported no remaining ADMA Biologics position as of Q4 2025 after selling out during the quarter.
Kilter Group sold 39 ADMA Biologics shares in Q4 2025, an estimated $572.
Kilter Group first reported a position in ADMA Biologics in Q2 2025 and held it in 2 quarters.
Kilter Group's ADMA Biologics position peaked at $711 in Q2 2025.
356 funds tracked by Wall St. Rank held ADMA Biologics as of Q4 2025.

Based on Kilter Group's 13F filing for Q4 2025, filed 13 Feb 2026.